Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options.

Video Overview
Trovagene Oncology Company Overview - April 2019
Recent News
Dec 9, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various...

Dec 4, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various...

Nov 14, 2019

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various...

More >

Stock Information
NASDAQTROV
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com

Contact

Events
September 10, 2019 - December 10, 2019
10:50am EDT

Dr. Thomas Adams, CEO and Chairman and Dr. Mark Erlancer, CSO, will present an overview of Trovagene and the Onvansertib Clinical Development Program at the HC Wainwright Conference in NYC on...

June 7, 2019 - September 7, 2019
8:00am PDT

Trovagene will be conducting a Company Business Update conference call and webcast on Friday, June 7th, 2019 at 11:00 am EDT (8:00 am PDT). The dial-in number is (866) 792-4365 [International...

April 1, 2019 - April 2, 2019

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will be presenting and conducting one-on-one meetings with investors at the Spring Investor Summit on April 1-2 at the Essex House...